Kura Oncology, Inc. has entered into an agreement with Janssen Pharmaceutica NV for an exclusive license to develop and commercialize tipifarnib in the field of oncology. Tipifarnib, a protein farnesyl transferase inhibitor, is a Phase II-ready program that has demonstrated clinical activity in certain cancers and may be further optimized using an appropriate patient selection strategy.   Kura will be responsible for development and commercialization of tipifarnib in oncology, and plans to advan...